These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 35645249)

  • 1. Natural Bioactive Products and Alzheimer's Disease Pathology: Lessons from
    Navarro-Hortal MD; Romero-Márquez JM; Osta S; Jiménez-Trigo V; Muñoz-Ollero P; Varela-López A
    Diseases; 2022 May; 10(2):. PubMed ID: 35645249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for β-amyloid peptide-induced toxicity.
    Lublin AL; Link CD
    Drug Discov Today Technol; 2013; 10(1):e115-e119. PubMed ID: 24050239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caenorhabditis elegans: a useful tool to decipher neurodegenerative pathways.
    Johnson JR; Jenn RC; Barclay JW; Burgoyne RD; Morgan A
    Biochem Soc Trans; 2010 Apr; 38(2):559-63. PubMed ID: 20298221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of policosanol from insect wax on amyloid β-peptide-induced toxicity in a transgenic Caenorhabditis elegans model of Alzheimer's disease.
    Zhang X; Ma C; Sun L; He Z; Feng Y; Li X; Gan J; Chen X
    BMC Complement Med Ther; 2021 Mar; 21(1):103. PubMed ID: 33785017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and characterization of a tractable C. elegans model of tauopathy.
    Russell JC; Lei H; Chaliparambil RK; Fish S; Markiewicz SM; Lee TI; Noori A; Kaeberlein M
    Geroscience; 2021 Oct; 43(5):2621-2631. PubMed ID: 34536202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.
    Volloch V; Olsen B; Rits S
    Ann Integr Mol Med; 2020; 2(1):90-114. PubMed ID: 32617536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human amyloid β peptide and tau co-expression impairs behavior and causes specific gene expression changes in Caenorhabditis elegans.
    Wang C; Saar V; Leung KL; Chen L; Wong G
    Neurobiol Dis; 2018 Jan; 109(Pt A):88-101. PubMed ID: 28982592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder.
    Calahorro F; Ruiz-Rubio M
    Invert Neurosci; 2011 Dec; 11(2):73-83. PubMed ID: 22068627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Aβ Containing Brain Extracts Having Different Effects in Alzheimer's Disease Transgenic
    Yang Y; Wang M; Yang P; Wang Z; Huang L; Xu J; Wang W; Yu M; Bu L; Fei J; Huang F
    Front Aging Neurosci; 2018; 10():208. PubMed ID: 30108498
    [No Abstract]   [Full Text] [Related]  

  • 10. Fucoidan inhibits amyloid-β-induced toxicity in transgenic Caenorhabditis elegans by reducing the accumulation of amyloid-β and decreasing the production of reactive oxygen species.
    Wang X; Yi K; Zhao Y
    Food Funct; 2018 Jan; 9(1):552-560. PubMed ID: 29260173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Neuroprotective Effects of a Natural Product Mixture against AD Hallmarks and Cognitive Decline in
    Griñán-Ferré C; Bellver-Sanchis A; Olivares-Martín M; Bañuelos-Hortigüela O; Pallàs M
    Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Caenorhabditis elegans as a model to study Alzheimer's disease and other neurodegenerative diseases.
    Alexander AG; Marfil V; Li C
    Front Genet; 2014; 5():279. PubMed ID: 25250042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AD "Statin": Alzheimer's Disorder is a "Fast" Disease Preventable by Therapeutic Intervention Initiated Even Late in Life and Reversible at the Early Stages.
    Volloch V; Olsen BR; Rits S
    Ann Integr Mol Med; 2020; 2(1):75-89. PubMed ID: 32201863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease.
    McColl G; Roberts BR; Pukala TL; Kenche VB; Roberts CM; Link CD; Ryan TM; Masters CL; Barnham KJ; Bush AI; Cherny RA
    Mol Neurodegener; 2012 Nov; 7():57. PubMed ID: 23171715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in the Modeling of Alzheimer's Disease.
    Sasaguri H; Hashimoto S; Watamura N; Sato K; Takamura R; Nagata K; Tsubuki S; Ohshima T; Yoshiki A; Sato K; Kumita W; Sasaki E; Kitazume S; Nilsson P; Winblad B; Saito T; Iwata N; Saido TC
    Front Neurosci; 2022; 16():807473. PubMed ID: 35431779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases.
    Chen X; Barclay JW; Burgoyne RD; Morgan A
    Chem Cent J; 2015; 9():65. PubMed ID: 26617668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deer antler extracts reduce amyloid-beta toxicity in a Caenorhabditis elegans model of Alzheimer's disease.
    Du F; Zhao H; Yao M; Yang Y; Jiao J; Li C
    J Ethnopharmacol; 2022 Mar; 285():114850. PubMed ID: 34801608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caenorhabditis elegans as a possible model to screen anti-Alzheimer's therapeutics.
    Paul D; Chipurupalli S; Justin A; Raja K; Mohankumar SK
    J Pharmacol Toxicol Methods; 2020; 106():106932. PubMed ID: 33091537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.